0.225

0.04% -0.000100

After Hours: .24 0.015 +6.67%

Theriva Biologics Inc (TOVX)

Overview News Price History Discussions Forecast

Theriva Biologics Inc stock is traded at $0.225, with a volume of 354.80K. It is down -0.04% in the last 24 hours and down -11.07% over the past month. Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Previous Close:

$0.2251

Open:

$0.2291

24h Volume:

354.80K

Relative Volume:

0.33

Market Cap:

$10.33M

Revenue:

Net Income/Loss:

$-21.46M

P/E Ratio:

-0.0888

EPS:

-2.5324

Net Cash Flow:

$-14.40M

1W Performance:

+3.93%

1M Performance:

-11.07%

6M Performance:

-2.13%

1Y Performance:

-45.86%

1-Day Range:

$0.225

$0.2377

1-Week Range:

$0.21

$0.2391

52-Week Range:

$0.1628

$0.8632

Theriva Biologics Inc Stock (TOVX) Company Profile

Name

Theriva Biologics Inc

Sector

Healthcare (1064)

Industry

Biotechnology (596)

Phone

301 417 4364

Address

9605 Medical Center Drive, Suite 270, Rockville

Employee

Twitter

Next Earnings Date

2026-11-11

Latest SEC Filings

TOVX's Discussions on Twitter

Compare TOVX vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TOVX Theriva Biologics Inc	0.225	10.12M	0	-21.46M	-14.40M	-2.5324
VRTX Vertex Pharmaceuticals Inc	503.50	127.93B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	203.21	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	726.47	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	912.87	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	207.68	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Theriva Biologics Inc Stock (TOVX) Latest News

Sep 30, 2026

Theriva™ Biologics anuncia la publicación en Nature Medicine de los resultados del ensayo clínico de Fase 2b VIRAGE con VCN-01 en el cáncer de páncreas metastásico - GlobeNewswire Inc.

Sep 30, 2026

Theriva publishes VCN-01 pancreatic cancer trial data in journal By Investing.com - Investing.com Canada

Sep 30, 2026

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine - Yahoo! Finance Canada

Sep 30, 2026

Sep 26, 2026

TOVX Should I Buy - Intellectia AI

Sep 26, 2026

Sep 04, 2026